A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines
BeOne Medicines
MSD R&D (China) Co., Ltd.
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sellas Life Sciences Group
Memorial Sloan Kettering Cancer Center
Pfizer
Dana-Farber Cancer Institute
The Lymphoma Academic Research Organisation
Gilead Sciences
St. Jude Children's Research Hospital
Peking University Third Hospital
Amgen
Regeneron Pharmaceuticals
Fondazione Italiana Linfomi - ETS
Allogene Therapeutics
Genmab
Allogene Therapeutics
Allogene Therapeutics
Autolus Limited
Hoffmann-La Roche
Memorial Sloan Kettering Cancer Center
University of Ulm
Lyell Immunopharma, Inc.
AstraZeneca
M.D. Anderson Cancer Center
Novartis
Ascentage Pharma Group Inc.
Celgene
The Lymphoma Academic Research Organisation
Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center, Cincinnati
Novartis
Ono Pharmaceutical Co. Ltd
Merck Sharp & Dohme LLC
Canadian Cancer Trials Group
Institute of Hematology & Blood Diseases Hospital, China
PeproMene Bio, Inc.
SecuraBio
Dana-Farber Cancer Institute
AstraZeneca
Regeneron Pharmaceuticals
Chengdu Zenitar Biomedical Technology Co., Ltd
Excyte Biopharma Ltd
Hoffmann-La Roche
Incyte Corporation
Memorial Sloan Kettering Cancer Center
Prescient Therapeutics, Ltd.
Regeneron Pharmaceuticals
Baylor College of Medicine
Haihe Biopharma Co., Ltd.